Sotera's Crack in the Armor Is a European Accent

Sotera Health reported on November 3 and, on the surface, nothing broke. Constant-currency revenue rose 4.4% to $325 million, adjusted EBITDA grew 4% to $171 million, and margins expanded nearly 100 basis points sequentially to 52.5%. Sterigenics grew 8.2% in constant currency with 57 basis points of segment margin expansion, Nelson Labs grew 9.2%, and Nordion's 11.5% decline was a cobalt-60 harvest-timing artifact that actually came in ahead of plan. Three segments, three different stories, all roughly on script.

Except for one sentence. The company's chief executive, Alton Shader, told investors the business is not going to do what it always does in the fourth quarter.

we did experience some softness at the end of Q3 and beginning of Q4 here. And based on what we are seeing in the business and what our customers are communicating to us, we are not expecting the sequential Q4 growth that we normally see and this really informed our guide.

That is the story. Not the 4.4%. The removal of a seasonal pattern that has been treated as a law of nature in this franchise.

The number that looked fine — and the sentence that didn't

Sterigenics had a genuinely strong quarter, and management was quick to itemize why: favorable facility shutdown days, a large customer that previously in-sourced ethylene-oxide sterilization and is now outsourcing to Sotera, and revenue flowing from the new North Carolina X-ray facility. Those three tailwinds are real and were flagged in prior calls. But tailwinds are not demand. Once you strip them out, the guide for roughly 6% constant-currency Sterigenics growth in Q4 works out to essentially flat sequential revenue versus Q3 — in a segment that has been growing volume and mix at a 3.4% clip as recently as this quarter.

The company's own keyword history makes the shift legible. Med device is the top-ranked theme this quarter, and it isn't a celebration. It arrives with a cluster of new qualifiers: European customer softness, a reduction in optimism from customers, and what Shader repeatedly called a bit of softness. None of those phrases appear anywhere in the prior year of calls. What does appear, over and over, is stable demand.

Europe is now the problem; the US is the alibi

Here is the contrast that matters. On the second-quarter call in August, Shader was asked directly about a competitor's warning signals and said this:

Three months later, the softness started mid-to-late in the third quarter and is continuing into the fourth. When Wolfe's Michael Polark asked whether the US was at risk, the answer was: “We are seeing relative stability out of the US at this time.” — Alton E. Shader, Chief Executive Officer · 2026-11-03 The company also volunteered where the softness lives — “So we started seeing some of the soft kind of mid to late Q3. And primarily, that softness came from our European customers” — Alton E. Shader, Chief Executive Officer · 2026-11-03.

That is a quiet irony worth flagging. In the same August call, Sotera argued its US-heavy footprint was a defensive advantage: “I know that we are higher indexed into the U.S. versus outside the U.S. compared to our primary competitor.” — Alton Shader, Chief Executive Officer · 2026-08-06 The insulation thesis now has a hole in it, and the pressure comes from the side of the business management historically talked about least.

To be fair, the analysts tried hard to escalate this into something bigger — Brett Fishbin asked whether it was broad across European customers (yes, not uniform), Jason Bednar asked whether it was channel destocking (the read was end-market volumes, not inventory). Shader was disciplined: flat sequential Q4, no specific segment commentary, planning cycle for 2027 not yet communicated. That discipline is appropriate. It is also exactly what you say when you don't yet know.

Nelson's advisory flip — a tailwind management won't bank

Nelson Labs is where a keyword genuinely inverted. For at least six quarters, Expert Advisory Services was a drag — a comp headwind, an FDA-activity casualty, a government-shutdown victim. On the May call, CFO Jon Lyons called it nearly over: “Expert Advisory Services is the last quarter we had that headwind that we are lapping over.” — Michael B. Petras, Chief Executive Officer and Chair · 2026-05-05 Now it is a tailwind, driving the segment to its best constant-currency growth in memory.

But the quality of that growth is visibly lower. Nelson's segment margin fell 199 basis points to 32.1%, which management attributed to business mix — EAS is project-based, lumpier, and less capital-efficient than routine lab testing. And Shader was careful not to let the Street extrapolate: “We do not expect long term EAS to be a larger percentage of the business and have this be a consistent mix shift towards EAS going forward.” — Alton E. Shader, Chief Executive Officer · 2026-11-03 Read that against the full-year guide, which now assumes a Nelson margin reduction that Sterigenics and Nordion expansion must offset to keep consolidated margins roughly flat. The strong execution is real; the mix underneath it is not the mix you want compounding.

The boring-but-real offset: cash, leverage, and a fading courtroom

Against all of that, the balance sheet keeps getting better. Net leverage reached 2.9x, inside the 2x-to-3x long-term target, and Moody's upgraded the credit in early October. Management reiterated a meaningful CapEx step-down into 2027 and the Investor Day free-cash-flow commitment of $500 million to $600 million across 2025–27. This matters because the equity has spent two years being valued on de-leveraging and cash conversion, not on growth. Capital expenditure of $46 million in the last filed quarter against free cash flow of $35 million, a 93% year-over-year improvement is the arithmetic the Street is actually underwriting. And it is working: effective net cash of roughly -$1.8 billion has narrowed steadily, with liabilities to assets down 4.2 percentage points year-over-year to 79.9%.

Litigation, meanwhile, has gone quiet — and quiet is itself informative. For a year the keyword set was dominated by Court, Plaintiffs, bellwether cases. This quarter those themes barely register; the update was procedural — a Georgia appellate ruling expected spring 2027, and first California trials calendared for January and April 2027. Nothing has been resolved, but the overhang has stopped being the narrative.

What the tape already knows

Sotera's stock has retraced to roughly $16, down 8.5% over 90 days and 18% from an August peak, and still 36% below its 2020 listing. The multiple has compressed accordingly: price-to-revenue of 4.2x versus 9.0x at the 2020 peak. This is a name the market has already stopped paying a premium for. So a demand qualifier that might cost a richly valued medtech three points lands differently here — the stock is not priced for perfection, but it is priced for the leverage-and-cash inflection to keep working, and any revenue durability question feeds directly into that.

The honest read: Sotera's fourth quarter is a test of whether a meaningful step down in CapEx can outrun a modest step down in demand. Management's language — resilient, stable, confident — is unchanged. The supporting evidence is thinner than it was three months ago. And the single most telling data point from the quarter isn't in the financials at all: it is that a company which has grown for twenty consecutive years had to tell investors it won't grow sequentially this time.